Alnylam Pharmaceuticals, Inc. (ALNY) Reports $492M Amvuttra Sales, Raises 2025 Revenue Guidance
We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Alnylam Pharmaceuticals, Inc. is one of them. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading biotech company specializing in RNA interference (RNAi) therapeutics, is advancing treatments for rare and prevalent diseases, notably transthyretin amyloidosis (ATTR). Its flagship product, Amvuttra (vutrisiran), treats both hereditary and cardiomyopathy forms of ATTR. In Q2 2025, Amvuttra sales surged to $492 milli ...